Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Tevogen Bio Holdings Inc. (TVGN)

6.99 -0.56 (-7.42%)
As of 2:12:36 PM EDT. Market Open.
Chart Range Bar
Loading chart for TVGN
  • Previous Close 7.55
  • Open 7.78
  • Bid 5.12 x 100
  • Ask 4.24 x 100
  • Day's Range 6.83 - 7.86
  • 52 Week Range 4.14 - 75.50
  • Volume 21,515
  • Avg. Volume 30,933
  • Market Cap (intraday) 29.108M
  • Beta (5Y Monthly) -0.30
  • PE Ratio (TTM) --
  • EPS (TTM) -8.08
  • Earnings Date (est.) May 15, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.

tevogen.com

18

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: TVGN

Trailing total returns as of 4/27/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TVGN
57.76%
S&P 500 (^GSPC)
4.82%

1-Year Return

TVGN
85.91%
S&P 500 (^GSPC)
29.86%

3-Year Return

TVGN
98.67%
S&P 500 (^GSPC)
73.51%

5-Year Return

TVGN
98.57%
S&P 500 (^GSPC)
71.38%

Earnings Trends: TVGN

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings --

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

0

Analyst Insights: TVGN

View More

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/4/2026
Analyst D. Boral Capital
Rating Action Downgrade
Rating Hold
Price Action --
Price Target --

Statistics: TVGN

View More

Valuation Measures

Annual
As of 4/24/2026
  • Market Cap

    30.73M

  • Enterprise Value

    46.48M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    10.59

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -416.53%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -26.83M

  • Diluted EPS (ttm)

    -8.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    552.37k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.77M

Compare To: TVGN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: TVGN

Fair Value

6.99 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: